ALC's Q2 earnings top estimates but revenues fall short, sending shares down more than 10% as margins tightened and 2025 sales outlook narrowed.

We recently published 10 Stocks Crash as AI Glow Fades. Alcon Inc. (NYSE:ALC) is one of Wednesday’s worst performers. Shares of Alcon Inc. snapped a six-day winning streak on Wednesday, losing 10.07 ...

Alcon (NYSE:ALC) stock continues to decline as J.P. Morgan downgrades the company following mixed Q2 2025 results and lowered sales guidance. Read more here.

Alcon affirmed fiscal year 2025 adjusted earnings of $3.05-$3.15 versus consensus of $3.12. The company lowered 2025 sales guidance from $10.4 billion-$10.5 billion to $10.3 billion-$10.4 billion, ...

Gain insights from Alcon Inc.'s Q2 2025 earnings call, including new product launches, strategic acquisitions, market trends, and updated financial guidance.

Alcon Inc (ALC) reports steady revenue growth and strategic acquisitions, despite facing market pressures and competitive challenges.

The analysts cut its rating on Alcon shares to “neutral” from “overweight” and lowered its price target to SFr 62.8 for June 2027, down from SFr 94.7 for June 2026. The reduced target reflects lower ...

Morgan Stanley analyst Patrick Wood lowered the firm’s price target on Alcon (ALC) to $80 from $84 and keeps an Equal Weight rating on the shares after updating the firm’s model for Q2 earnings that ...

Alcon India unveils UNITY VCS and UNITY CS with superior efficiency for vitreoretinal and cataract surgery: Our Bureau, Bengaluru Thursday, August 21, 2025, 14:40 Hrs [IST] Alcon, ...

Baird analyst Jeff Johnson lowered the firm’s price target on Alcon (ALC) to $95 from $108 and keeps an Outperform rating on the shares. The frim ...

In partnership with Great Place to Work, PEOPLE's ninth annual list highlights businesses making a difference in the lives of ...

Eyecare specialist Iantrek has raised $42m to support the US launch of its allogeneic graft for treating glaucoma.